Table 5 Comparative analysis of integrative genomic approach and cancer panels. The numbers corresponding to the three cancer panels are hypothetical (based on the panel design) and not based on experimental results
Genomic approach | Mean number of cancer-relevant somatic mutations (range) | Number of patients with tier 1 drug recommendations | Number of patients with tier 2 drug recommendations | Number of patients with actionable alterations | Mean number of actionable alterations (range) |
|---|---|---|---|---|---|
Ion AmpliSeq Cancer Hotspot Panel v2 | 1.3 (0–4) | 24 (52 %) | 16 (35 %) | 24 (52 %) | 0.65 (0–3) |
Oncomine Comprehensive Panel | 2.5 (0–11) | 39 (85 %) | 24 (52 %) | 41 (89 %) | 2.4 (0–6) |
FoundationOne | 3.7 (0–22) | 39 (85 %) | 24 (52 %) | 41 (89 %) | 2.6 (0–7) |
This study | 17.3 (1–79) | 40 (87 %) | 26 (57 %) | 42 (91 %) | 4.9 (0–14) |